EUVIMEDEUVIMED entdecken
Crossref

Examining psychiatric and cognitive adverse effects of brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel in a veteran population

Poojith Nuthalapati, Danny DeBonis, Margaret Gopaul, Chinenye M Okafor, Michelle Orner, Anthony D Jimenez, Hamada H Altalib

Epilepsy & Behavior · 2025

DOI: 10.1016/j.yebeh.2025.110557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Poojith Nuthalapati und 6 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, Department of Neurology, 50 York Street, New Haven, CT 06511, United States; West Haven Veterans Affairs Hospital, Departmen…. Hauptthemen laut MEDLINE: Veterans, Anticonvulsants, Epilepsy, Mental Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Eisai Inc, Sunovian Pharmaceuticals, Eisai Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Epilepsy is a chronic neurological disorder, affecting approximately 50 million people worldwide. There is limited data on the use of newer anti-seizure medicines (ASMs) and their cognitive and psychiatric adverse effects (AEs), despite increasing use. We aimed to describe the AE profile of newer ASMs in the real-world veteran population with Epilepsy comparing those who develop cognitive or psychiatric AEs to those who did not. METHODS: A retrospective analysis of veterans (n = 2636) diagnosed with epilepsy via ICD-10 codes was conducted in collaboration with the Veterans Affairs (VA) Office Quality and Patient Safety Analytics and Performance Integration program. Neurology notes of veterans diagnosed with epilepsy, between January 2011 and June 2022 across the VA system were sampled to evaluate cognitive and psychiatric AEs. For this index study, only patients who were prescribed any of the five newer anti-seizure medications (brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel) were included. Selection of these ASMs were made a priori as these were the most recently approved ASMs for use in the VA. RESULTS: Among the 2636 Veterans that were included in the index study, median age (Q1-Q3) was 64 (50-73) years with 88.1 % male participants, a population known to have higher prevalence of psychiatric and cognitive disorders. Overall, 70.7 % White Veterans, and 6.5 % Hispanic. 86.8 % were prescribed lacosamide while only 4.1 %, 4.3 %, 4.4 %, and 4.8 % were prescribed perampanel, clobazam, brivaracetam, and eslicarbazepine respectively. Overall, 63 (2.4 %) and 39 (1.5 %) Veterans reported cognitive and psychiatric AEs, respectively. Veterans with epilepsy were more likely to experience cognitive AEs if they were independently older (p = 0.004) and on Perampanel (OR 2.58, p = 0.03). Similarly, psychiatric AEs were more likely among those on Perampanel (OR 4.49), whereas they were less frequent in those taking frequent lacosamide (OR 0.38). Cognitive or psychiatric AEs often lead to treatment discontinuation in this population. CONCLUSION: In a population of veterans with epilepsy, clinicians should exercise caution in monitoring for cognitive and psychiatric adverse effects prescribed with the newer ASMs. Further research could help elucidate the dosage and delay at which these side effects would occur after treatment initiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VeteransAnticonvulsantsEpilepsyMental DisordersCognitive DysfunctionCognition DisordersHumansMaleFemaleMiddle AgedLacosamideRetrospective StudiesAgedNitrilesDibenzazepinesClobazamAdultPyridonesPyrrolidinones

Stichwörter der Autor:innen

Antiseizure medicationBrivaracetamClobazamEpilepsy psychiatric and cognitive adverse effectsEslicarbazepineLacosamidePerampanel

Substanzen

AnticonvulsantsLacosamideperampanelNitrileseslicarbazepineDibenzazepinesClobazambrivaracetamPyridonesPyrrolidinones

Autor:innen und Institutionen

  • Yale School of Medicine, Department of Neurology, 50 York Street, New Haven, CT 06511, United States; West Haven Veterans Affairs Hospital, Department of Neurology, 1050 Camel Avenue, West Haven CT, United States.
  • Medical University of South Carolina Health, Department of Internal Medicine, Florence, SC, United States.
  • Salt Lake City Veterans Affairs Hospital, Department of Neurology, 500 Foothill Drive, Salt Lake City, UT 84148, United States.
  • Yale School of Medicine, Department of Neurology, 50 York Street, New Haven, CT 06511, United States; West Haven Veterans Affairs Hospital, Department of Neurology, 1050 Camel Avenue, West Haven CT, United States. Elect…

Förderung

  • Eisai Inc
  • Sunovian Pharmaceuticals
  • Eisai Canada

Zitieren

APA

Nuthalapati, P., DeBonis, D., Gopaul, M., Okafor, C. M., Orner, M., Jimenez, A. D., & Altalib, H. H. (2025). Examining psychiatric and cognitive adverse effects of brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel in a veteran population. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110557

Vancouver

Nuthalapati P, DeBonis D, Gopaul M, Okafor CM, Orner M, Jimenez AD, et al. Examining psychiatric and cognitive adverse effects of brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel in a veteran population. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2025.110557

BibTeX
@article{Nuthalapati2025,
  author = {Nuthalapati, Poojith and DeBonis, Danny and Gopaul, Margaret and Okafor, Chinenye M and Orner, Michelle and Jimenez, Anthony D and Altalib, Hamada H},
  title = {Examining psychiatric and cognitive adverse effects of brivaracetam, clobazam, lacosamide, eslicarbazepine, and perampanel in a veteran population},
  journal = {Epilepsy & Behavior},
  year = {2025},
  doi = {10.1016/j.yebeh.2025.110557}
}
Kostenlos starten →